SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia

  title={SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia},
  author={Fatih M. Uckun and Sanjive Qazi},
  booktitle={Journal of cancer therapy},
The identification of SYK as a master regulator of apoptosis controlling the activation of the PI3-K/AKT, NFκB, and STAT3 pathways-three major anti-apoptotic signaling pathways in B-lineage leukemia/lymphoma cells-prompts the hypothesis that rationally designed inhibitors targeting SYK may overcome the resistance of malignant B-lineage lymphoid cells to apoptosis and thereby provide the foundation for more effective multi-modality treatment regimens for poor prognosis B-precursor acute… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 20 references

Long- Term Outcome in Children with Relapsed ALL by Risk- Stratified Salvage Therapy: Results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87

H. G. Einsiedel, A. von Stackelberg, +3 authors G. Janka-Schaub
Journal of Clinical Oncology, Vol. 23, No. 31, 2005, pp. 7942-7950. • 2005
View 4 Excerpts
Highly Influenced

Protein kinase inhibitors against malignant lymphoma.

Expert opinion on pharmacotherapy • 2013
View 4 Excerpts

Lipid Spheres as Attractive Nanoscale Drug Delivery Platforms for Cancer Therapy

S. H. Yiv, F. M. Uckun
Journal of Nanomedicine & Nanotechnology, Vol. 3, 2012, p. 128. OPEN ACCESS JCT • 2012
View 1 Excerpt

Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery.

Proceedings of the National Academy of Sciences of the United States of America • 2012
View 1 Excerpt

Childhood Leukemia: A Practical Handbook

G. H. Reaman, F. O. Smith
Springer Verlag, Heidelberg-Berlin, 2011. • 2011
View 2 Excerpts

Similar Papers

Loading similar papers…